Reactive arthritis.
During the past year, no big advances were reported in understanding the pathogenesis or treatment of reactive arthritis (ReA). The need for generally accepted diagnostic criteria has become a central issue. Regarding pathogenesis, attention has been drawn to a similarity between ReA and the experimental antigen-induced arthritis. Molecular mechanisms of the HLA-B27-associated pathogenesis have remained, in spite of intensive research, so far a mystery. It is apparent that antibiotics have no effect on the fully developed reactive arthritis, with the exception of patients with Chlamydia-triggered ReA, who might benefit from a course of antibiotics.
Department of Medicine, Turku University, Finland. paavo.toivanen@utu.fi
A
A
Toivanen
P
P
Toivanen
D000818:Animals; D016918:Arthritis, Reactive / Q000097:blood / Q000145:classification / Q000188:drug therapy / Q000382:microbiology; D002690:Chlamydia Infections / Q000382:microbiology; D002692:Chlamydia trachomatis / Q000235:genetics / Q000302:isolation & purification; D002939:Ciprofloxacin / Q000627:therapeutic use; D004269:DNA, Bacterial / Q000032:analysis; D004311:Double-Blind Method; D015796:HLA-B27 Antigen / Q000097:blood; D006801:Humans; D000091402:Prohibitins; D016032:Randomized Controlled Trials as Topic; D015009:Yersinia Infections / Q000382:microbiology; D015008:Yersinia enterocolitica / Q000235:genetics / Q000302:isolation & purification
D004269:DNA, Bacterial; D015796:HLA-B27 Antigen; C000717331:PHB2 protein, human; D000091402:Prohibitins; D002939:Ciprofloxacin